Medical Bulletin 06/March/2026 - Video

Here are the top medical news for today:

Study Finds Human Protein Linked to Reversing Brain Aging

Aging often brings a gradual decline in memory and learning ability, largely because neural stem cells lose their capacity to produce new neurons. For decades, this slowdown has been viewed as an unavoidable consequence of growing older. However, researchers at the National University of Singapore (NUS) have uncovered evidence suggesting this process may not be entirely irreversible.

In a study published in Science Advances, the team identified a key protein called cyclin D-binding myb-like transcription factor 1 (DMTF1) as a central regulator of neural stem cell function. Transcription factors like DMTF1 control how genes are switched on or off. When scientists examined aged human and mouse neural stem cells, they found that DMTF1 was present but largely silenced, leaving the cells unable to regenerate effectively.

When researchers restored DMTF1 activity in these aged stem cells, the results were striking. The cells regained their ability to proliferate, essentially reviving their regenerative potential. According to senior author Derrick Sek Tong Ong, this finding shed light on mechanisms that have long been poorly understood in brain aging.

The team also investigated how DMTF1 overcomes one of aging’s most well-known barriers: telomere shortening. Telomeres, protective caps at the ends of chromosomes, naturally shrink as cells divide, eventually triggering cellular senescence. Yet DMTF1 appeared to bypass this limitation by activating growth-related genes through chromatin remodeling, even in cells already affected by shortened telomeres.

While the research was conducted in laboratory models rather than living humans, it provides a promising framework for future therapies. Instead of reversing aging, targeting DMTF1 could potentially help the brain maintain its ability to repair and regenerate neurons, preserving cognitive function later in life.

REFERENCE: Yajing Liang, Oleg V. Grinchuk, et al.; DMTF1 up-regulation rescues proliferation defect of telomere dysfunctional neural stem cells via the SWI/SNF-E2F axis; Science Advances; DOI: 10.1126/sciadv.ady5905

Chronic Alcohol Consumption Associated With Higher Rectal Cancer Rates: Study

Lifetime heavy alcohol consumption significantly raises the risk of developing colorectal cancer, particularly rectal cancer, according to a new study published in CANCER. The findings emphasize that cumulative alcohol exposure over decades—not just current drinking habits—plays a major role in cancer risk.

Researchers analyzed health data from 88,092 adults who were cancer-free at enrollment in the National Cancer Institute’s Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Participants were followed for up to 20 years, during which 1,679 individuals were diagnosed with colorectal cancer.

Among current drinkers, those classified as heavy lifetime drinkers—averaging 14 or more drinks per week—had a 25% higher risk of colorectal cancer compared with people who averaged less than one drink per week over their lifetime.

The association was even more pronounced for rectal cancer, where heavy drinkers faced a 95% higher risk. Additionally, individuals who drank heavily across many years of adulthood had a 91% greater risk of colorectal cancer than consistent light drinkers.

Encouragingly, former drinkers did not show an increased colorectal cancer risk compared to light drinkers. They also had lower odds of developing colorectal adenomas, which are noncancerous growths that can later become malignant.

Although data on former drinkers were limited, the findings suggest that quitting alcohol may help lower long-term cancer risk.

Scientists believe alcohol may contribute to cancer development through toxic breakdown products like acetaldehyde or by disrupting gut microbiota and promoting inflammation. Further research is needed to clarify these mechanisms, but the results reinforce public health advice to limit alcohol intake to reduce cancer risk.

REFERENCE: Caitlin P. O’Connell, Sonja I. Berndt, Kenechukwu Chudy‐Onwugaje, Andrew Kunzmann, Wen‐Yi Huang, Kathryn Hughes Barry, Erikka Loftfield. Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer, 2026; 132 (3) DOI: 10.1002/cncr.70201

Scientists Uncover Why Chronic Constipation Treatments Often Fail

Scientists at Nagoya University have identified a previously unrecognized bacterial partnership in the gut that may contribute to chronic constipation. Their findings, published in Gut Microbes, show that two microbes—Akkermansia muciniphila and Bacteroides thetaiotaomicron—work together to degrade the protective mucus layer lining the colon.

This mucus, made largely of colonic mucin, acts as a lubricant that keeps stool soft and easy to pass while shielding the intestinal wall from bacterial invasion. The researchers discovered that the two bacteria dismantle this barrier in a coordinated, stepwise process. First, B. thetaiotaomicron produces an enzyme called sulfatase, which removes protective sulfate groups from mucin. Once these defenses are stripped away, A. muciniphila can digest the exposed mucus. When mucin levels drop too low, stool loses moisture, becomes dry and hard, and constipation develops.

The study also revealed a notable connection to Parkinson's disease. Patients with Parkinson’s—many of whom experience severe constipation decades before motor symptoms appear—were found to have elevated levels of these mucus-degrading bacteria. This suggests that microbial imbalance, not just nerve damage, may contribute to early digestive symptoms in the disease.

To test a potential solution, researchers genetically modified B. thetaiotaomicron so it could no longer produce the sulfatase enzyme. When introduced into germ-free mice alongside A. muciniphila, the animals did not develop constipation, and their mucus layer remained intact.

These findings suggest that targeting bacterial sulfatase activity could offer a new treatment strategy—one that focuses on protecting the colon’s mucus barrier rather than simply stimulating bowel movement.

REFERENCE: Tomonari Hamaguchi, Noriaki Gibo, Misuzu Ohara, Mikako Ito, Tomoyuki Ogura, Jun-Ichi Takeda, Hiroshi Nishiwaki, Fei Zhao, Ryo Kinoshita-Daitoku, Masashi Hattori, Koji Nonogaki, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Masaaki Hirayama, Mitsuhiro Fujishiro, Hiroki Kawashima, Kinji Ohno. Bacterial constipation: Mucin-degrading intestinal commensal bacteria cause constipation. Gut Microbes, 2026; 18 (1) DOI: 10.1080/19490976.2025.2596809